A director at Opko Health Inc bought 500,000 shares at 1.482USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
A director at Asa Gold & Precious Metals Ltd bought 29,700 shares at 21.999USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at Westin St. Francis hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 15th at 3:00 p.m. Pacific time. The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website . About...
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET. A live webcast of the presentation will be available on the investor section of the Anaptys website at . A replay of the webcast will be availabl...
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), announces dosing of the first participant in ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.